<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We inquired if fluorescence-guided surgery (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FGS</z:e>) could improve surgical outcomes in fluorescent orthotopic <z:mp ids='MP_0003815'>nude</z:mp> mouse models of human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We established fluorescent orthotopic mouse models of human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> expressing a fluorescent protein </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> were resected under bright light surgery (BLS) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FGS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Pre- and post-operative images with the OV-100 Small Animal Imaging System (Olympus Corp, Tokyo Japan) were obtained to assess the extent of surgical resection </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> mice with <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> that had undergone <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FGS</z:e> had complete resection compared with 58% of mice in the BLS group (P = 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FGS</z:e> resulted in decreased recurrence compared with BLS (33% versus 62%, P = 0.049) and lengthened disease-free median survival from 9 to &gt;36 wk </plain></SENT>
<SENT sid="6" pm="."><plain>The median overall survival increased from 16 wk in the BLS group to 31 weeks in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FGS</z:e> group </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FGS</z:e> resulted in a cure in 67% of mice (alive without evidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> at &gt;6 mo after surgery) compared with only 37% of mice that underwent BLS (P = 0.049) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Surgical outcomes in orthotopic <z:mp ids='MP_0003815'>nude</z:mp> mouse models of human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> were significantly improved with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FGS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The present study can be translated to the clinic by various effective methods of fluorescently labeling <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>